Advertisement

Aging Clinical and Experimental Research

, Volume 21, Issue 3, pp 201–209 | Cite as

Immunosenescence and vaccine failure in the elderly

  • Beatrix Grubeck-LoebensteinEmail author
  • Silvia Della Bella
  • Anna Maria Iorio
  • Jean-Pierre Michel
  • Graham Pawelec
  • Rafael Solana
Review Article

Abstract

An age-related decline in immune responses in the elderly results in greater susceptibility to infection and reduced responses to vaccination. This decline in immune function affects both innate and adaptive immune systems. A meeting of experts in immunology and gerontology in Paris, France, in April 2008, considered current understanding of immunosenescence and its clinical consequences. Essential features of immunosenescence include: reduced natural killer cell cytotoxicity on a per cell basis; reduced number and function of dendritic cells in blood; decreased pools of naive T and B cells; and increases in the number of memory and effector T and B cells. In particular, an accumulation of late differentiated effector T cells, commonly associated with cytomegalovirus infection, contributes to a decline in the capacity of the adaptive immune system to respond to novel antigens. Consequently, vaccine responsiveness is compromised in the elderly, especially frail patients. Strategies to address the effects of immunosenescence include ensuring that seroprotective antibody levels against preventable infectious diseases are maintained throughout adulthood, and improving diet and exercise to address the effects of frailty. New vaccines are being developed, such as intradermal and high-dose vaccines for influenza, to improve the efficacy of immunization in the elderly. In the future, the development and use of markers of immunosenescence to identify patients who may have impaired responses to vaccination, as well as the use of end-points other than antibody titers to assess vaccine efficacy, may help to reduce morbidity and mortality due to infections in the elderly.

Keywords

frailty immunosenescence innate immunity vaccination 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lutz W, Sanderson W, Scherbov S. Doubling of world population unlikely. Nature 1997; 387: 803–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in the elderly. Clin Infect Dis 2008; 46: 1078–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity 2006; 24: 491–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Di Santo JP. Natural killer cells: diversity in search of a niche. Nat Immunol 2008; 9: 473–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Kutza J, Murasako DM. Effects of aging on natural killer cell activity and activation by interleukin-2 and IFN-alpha. Cell Immunol 1994; 155: 195–204.PubMedCrossRefGoogle Scholar
  6. 6.
    Kutza J, Murasko DM. Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples. Mech Ageing Dev 1996; 90: 209–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine 2000; 18: 1613–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Ogata K, An E, Shioi Y et al. Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 2001; 124: 392–7.PubMedCrossRefGoogle Scholar
  9. 9.
    De la Rosa O, Pawelec G, Peralbo E et al. Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology 2006; 7: 471–81.CrossRefGoogle Scholar
  10. 10.
    Ogata K, Yokose N, Tamura H et al. Natural killer cells in the late decades of human life. Clin Immunol Immunopathol 1997; 84: 269–75.PubMedCrossRefGoogle Scholar
  11. 11.
    Remarque E, Pawelec G. T cell immunosenescence and its clinical relevance in man. Rev Clin Gerontol 1998; 8: 5–14.CrossRefGoogle Scholar
  12. 12.
    Mysliwska J, Trzonkowski P, Szmit E, Brydak LB, Machala M, Mysliwski A. Immunomodulating effect of influenza vaccination in the elderly differing in health status. Exp Gerontol 2004; 39: 1447–58.PubMedCrossRefGoogle Scholar
  13. 13.
    Sansoni P, Cossarizza A, Brianti V et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993; 82: 2767–73.PubMedGoogle Scholar
  14. 14.
    Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995; 16: 12–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Shortman K, Naik SH, Steady-state and inflammatory dendritic- cell development. Nat Rev Immunol 2007; 7: 19–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Ueno H, Klechevsky E, Morita R et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219: 118–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275–306.PubMedCrossRefGoogle Scholar
  18. 18.
    Della Bella S, Bierti L, Presicce P et al. Peripheral blood dendritic cells and monocytes are differentially regulated in the elderly. Clin Immunol 2007; 122: 220–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Varas A, Sacédon R, Hernandez-López C et al. Age-dependent changes in thymic macrophages and dendritic cells. Microsc Res Tech 2003; 62: 501–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Bhushan M, Cumberbatch M, Dearman RJ, Andrew SM, Kimber I, Griffiths CE. Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br J Dermatol 2002; 146: 32–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Tarazona R, Gayoso I, Alonso C et al. NK cells in human ageing. In Fülöp T, Hirokawa H, Pawelec G, Franceschi C, eds. Ageing, Immunity and Inflammation. Berlin: Springer Science 2009 (in press).Google Scholar
  22. 22.
    Franceschi C, Bonafè M, Valensin S et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000; 908: 244–54.CrossRefGoogle Scholar
  23. 23.
    Steinmann GG, Klaus B, Müller-Hermelink HK. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand J Immunol 1985; 22: 563–75.CrossRefGoogle Scholar
  24. 24.
    Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005; 114: 37–43.PubMedCrossRefGoogle Scholar
  25. 25.
    Pfister G, Weiskopf D, Lazuardi L et al. Naïve T cells in the elderly. Are they still there? Ann NY Acad Sci 2006; 1067: 152–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Saurwein-Teissl M, Lung TL, Marx F et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168: 5893–9.PubMedGoogle Scholar
  27. 27.
    Schwaiger S, Wolf A-M, Robatscher P, Jenewein B, Grubeck-Loebenstein B. IL-4 producing CD8+ T cells with a CD62L++(bright) phenotype accumulate in a subgroup of older adults and are associated with the maintenance of intact humoral immunity in old age. J Immunol 2003; 170: 613–9.PubMedGoogle Scholar
  28. 28.
    Herndler-Brandstetter D, Schwaiger S, Veel E et al. CD25-expressing CD8+ T cells are potent memory cells in old age. J Immunol 2005; 175: 1566–74.PubMedGoogle Scholar
  29. 29.
    Lugli E, Pinti M, Nasi M et al. Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. Cytometry A 2007; 71: 334–44.PubMedGoogle Scholar
  30. 30.
    Weng N. Aging of the immune system: how much can the adaptive immune system adapt? Immunity 2006; 24: 495–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Almanzar G, Schwaiger S, Jenewein B et al. Long term CMV infection leads to significant changes in the composition of the CD8+ T cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 2005; 79: 3675–83.PubMedCrossRefGoogle Scholar
  32. 32.
    Khan N, Shariff N, Cobbold M et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169: 1984–92.PubMedGoogle Scholar
  33. 33.
    Ouyang Q, Wagner WM, Voehringer D et al. Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol 2003; 38: 911–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000; 121: 187–201.PubMedCrossRefGoogle Scholar
  35. 35.
    Pawelec G, Ferguson FG, Wikby A. The SENIEUR protocol after 16 years. Mech Ageing Dev 2001; 122: 132–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol 2002; 37: 445–53.PubMedCrossRefGoogle Scholar
  37. 37.
    Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev 1998; 102: 187–98.PubMedCrossRefGoogle Scholar
  38. 38.
    Ferguson FG, Wikby A, Maxson P, Olsson J, Johansson B. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci 1995; 50: B378–82.PubMedCrossRefGoogle Scholar
  39. 39.
    Hadrup SR, Strindhall J, Kollgaard T et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional CMV specific T cells in the very elderly. J Immunol 2006; 176: 2645–53.PubMedGoogle Scholar
  40. 40.
    Wikby A, Nilsson BO, Forsey R et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late functioning. Mech Ageing Dev 2006; 127: 695–704.PubMedCrossRefGoogle Scholar
  41. 41.
    Swain S, Clise-Dwyer K, Haynes L. Homeostasis and the age-associated defect of CD4 T cells. Semin Immunol 2005; 17: 370–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Kovaiou RD, Weiskirchner I, Keller M, Pfister G, Cioca DP, Grubeck-Loebenstein B. Age-related differences in phenotype and function of CD4+ T cells are due to a phenoytypic shift from naïve to memory effector CD4+ T cells. Int Immunol 2005; 17: 1359–66.PubMedCrossRefGoogle Scholar
  43. 43.
    Kang I, Hong MS, Nolasco H et al. Age-associated change in the frequency of memory CD4+ T cells impair long term CD4+ T cell responses to influenza vaccine. J Immunol 2004; 173: 673–81.PubMedGoogle Scholar
  44. 44.
    Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing 2008; 5: 6.PubMedCrossRefGoogle Scholar
  45. 45.
    Allman D, Miller JP. B cell development and receptor diversity during aging. Curr Opin Immunol 2005; 17: 463–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Johnson SA, Cambier JC. Ageing, autoimmunity and arthritis: senescence of the B cell compartment — implications for humoral immunity. Arthritis Res Ther 2004; 6: 131–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Frasca D, Riley RL, Blomberg BB. Humoral immune response and B cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol 2005; 17: 378–84.PubMedCrossRefGoogle Scholar
  48. 48.
    Haynes L, Eaton SM. The effect of age on the cognate function of CD4+ T cells. Immunol Rev 2005; 205: 220–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Roubenoff R. Physical activity, inflammation, and muscle loss. Nutr Rev 2007; 65: S208–12.PubMedCrossRefGoogle Scholar
  50. 50.
    Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002; 211: 659–66.CrossRefGoogle Scholar
  51. 51.
    Horiuchi S, Wilmoth JR. Age patterns of the life table aging rate for major causes of death in Japan, 1951–1990. J Gerontol A Biol Sci Med Sci 1997; 52: B67–77.PubMedCrossRefGoogle Scholar
  52. 52.
    Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005; 23: 3232–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Brydak LB, Machala M, Mysliwska J, Mysliwska A, Trzonkowski P. Immune response to influenza vaccination in an elderly population. J Clin Immunol 2003; 23: 214–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37: 529–49.PubMedCrossRefGoogle Scholar
  55. 55.
    Kaml M, Weiskirchner I, Keller M et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titres. Vaccine 2006; 24: 6808–11.PubMedCrossRefGoogle Scholar
  56. 56.
    Keren G, Sergev S, Morag A, Zakay-Rones Z, Barzilai A, Rubinstein E. Failure of influenza vaccination in the aged. J Med Virol 1988; 25: 85–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Gross PA, Quinnan GV Jr, Weksler ME, Gaerlan PF, Denning CR. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc 1988; 36: 209–12.PubMedGoogle Scholar
  58. 58.
    Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24: 1159–69.PubMedCrossRefGoogle Scholar
  59. 59.
    Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–56.PubMedCrossRefGoogle Scholar
  60. 60.
    Bandeen-Roche K, Xue QL, Ferrucci L et al. Phenotype of frailty: characterization in the women’s health and aging studies. J Gerontol A Biol Sci Med Sci 2006; 61: M262–6.CrossRefGoogle Scholar
  61. 61.
    Gross PA, Quinnan GV, Weksler ME, Setia U, Douglas RG. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine 1989; 7: 303–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Fülöp T, Wagner JR, Khalil A, Weber J, Trottier L, Payette H. Relationship between the response to influenza vaccination and the nutritional status in institutionalized elderly subjects. J Gerontol A Med Sci Biol Sci 1999; 54: M59–64.CrossRefGoogle Scholar
  63. 63.
    Fried LP, Walston J. Frailty and failure to thrive. In Hazzard WR, Blass JP, Ettinger WH Jr, Halter JB, Ouslander J, eds. Principles of Geriatric Medicine and Gerontology. 4th ed. New York: McGraw Hill, 1998: 1387–402.Google Scholar
  64. 64.
    Binder EF, Schechtman KB, Ehsani AA et al. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc 2002; 50: 1921–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Walston J, McBurnie MA, Newman A et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 2333–41.PubMedCrossRefGoogle Scholar
  66. 66.
    Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003; 114: 180–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. J Am Geriatr Soc 2007; 55: 864–71.PubMedCrossRefGoogle Scholar
  68. 68.
    Pawelec G. Immunosenescence and vaccination. Immun Ageing 2005; 2: 16.PubMedCrossRefGoogle Scholar
  69. 69.
    Fülöp T, Larbi A, Hirokawa K et al. Immunosupportive therapies in aging. Clin Interventions Aging 2007; 2: 1–22.CrossRefGoogle Scholar
  70. 70.
    Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Alore H, Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. N Engl J Med 2002; 347: 1068–74.PubMedCrossRefGoogle Scholar
  71. 71.
    Kohut ML, Cooper MM, Nickolaus MS, Russel DR, Cunnick JE. Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals. J Gerontol A Biol Sci Med Sci 2002; 57: M557–62.PubMedCrossRefGoogle Scholar
  72. 72.
    Chandra RK. Influence of multinutrient supplement on immune responses and infection-related illness in 50–65 year old individuals. Nutr Res 2002; 22: 5–11.CrossRefGoogle Scholar
  73. 73.
    Lesourd B. Nutritional factors and immunological ageing. Proc Nutr Soc 2006; 65: 319–25.PubMedCrossRefGoogle Scholar
  74. 74.
    Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 2008; 23: 64–74.CrossRefGoogle Scholar
  75. 75.
    Hara M, Tanaka K, Hirota Y. Immune response to influenza vaccine in healthy adults and the elderly: associaton with nutritional status. Vaccine 2005; 23: 1457–63.PubMedCrossRefGoogle Scholar
  76. 76.
    Kiecolt-Glaser JK, Glaser R, Gravenstein S, Malarkey WB, Sheridan J. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci USA 1996; 93: 3043–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Iorio AM, Alatri A, Camilloni B, Neri M, Baglio G, Donatelli I. Antibody response to 1995–1996 influenza vaccine in institutionalized and non-institutionalized elderly women. Gerontology 1999; 45: 31–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Hayney MS, Love GD, Buck JM, Ryff CD, Singer B, Muller D. The association between psychosocial factors and vaccine-induced cytokine production. Vaccine 2003; 21: 2428–32.PubMedCrossRefGoogle Scholar
  79. 79.
    Vedhara K, Bennett PD, Clark S et al. Enhancement of antibody responses to influenza vaccination in the elderly following a cognitive-behavioural stress management intervention. Psychother Psychosom 2003; 72: 245–52.PubMedCrossRefGoogle Scholar
  80. 80.
    Couch RB, Winokur P, Brady R et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25: 7656–63.PubMedCrossRefGoogle Scholar
  81. 81.
    Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198: 650–8.PubMedCrossRefGoogle Scholar
  82. 82.
    de Brujin IA, Meyer I, Gerez L, Nauta J, Giezman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted or conventional influenza vaccines in the elderly. Vaccine 2007; 26: 119–27.CrossRefGoogle Scholar
  83. 83.
    Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyana CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75: 12182–7.PubMedCrossRefGoogle Scholar
  84. 84.
    McElhaney JE, Xie D, Hager WD et al. T cell reponses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176: 6333–9.PubMedGoogle Scholar
  85. 85.
    Trzonkowski P, Mysliwska J, Pawelec G, Mysliwski A. From bench to bedside and back: the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology 2009: 10: 83–94.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Internal Publishing Switzerland 2009

Authors and Affiliations

  • Beatrix Grubeck-Loebenstein
    • 1
    Email author
  • Silvia Della Bella
    • 2
  • Anna Maria Iorio
    • 3
  • Jean-Pierre Michel
    • 4
  • Graham Pawelec
    • 5
  • Rafael Solana
    • 6
  1. 1.Institute for Biomedical Aging ResearchAustrian Academy of SciencesInnsbruckAustria
  2. 2.Laboratory of Immunology, Dipartimento di Scienze e Tecnologie BiomedicheUniversità degli Studi di MilanoItaly
  3. 3.Department of Medical and Surgical Specialities and Public HealthUniversity of PerugiaItaly
  4. 4.University Hospitals of GenevaSwitzerland
  5. 5.Centre for Medical Research, ZMFUniversity of TübingenGermany
  6. 6.Department of ImmunologyUniversity of CordobaSpain

Personalised recommendations